Related Experiment Video
Updated: Apr 3, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
Hepatitis B: encouraging the use of interferon
Thinesh Lee Krishnamoorthy1, David Mutimer
1aLiver and Hepatobiliary Unit bNIHR Liver Biomedical Research Unit, Queen Elizabeth Hospital, Birmingham, UK.
Current Opinion in Infectious Diseases
|September 19, 2015
Summary
Interferon (IFN) therapy shows promise for chronic hepatitis B treatment, potentially shortening nucleos(t)ide analogue duration and improving outcomes in certain patient groups. Further research is needed to confirm these findings for clinical practice.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B is a significant risk factor for liver cancer and cirrhosis.
- Interferon (IFN)-based therapies offer high rates of sustained virological and serological control but are often limited by side effects.
- Optimizing IFN use in chronic hepatitis B treatment is crucial for improving patient outcomes.
Purpose of the Study:
- To review recent advancements in the use of Interferon (IFN) for treating chronic hepatitis B.
- To explore strategies for enhancing IFN efficacy while minimizing treatment exposure.
- To identify patient groups unlikely to benefit from current treatment endpoints.
Main Methods:
- Review of recent developments in Interferon (IFN) therapy for chronic hepatitis B.
- Analysis of strategies to improve efficacy and limit treatment duration.
- Evaluation of potential biomarkers and treatment rules.
Main Results:
- Host genetics (HLA, IL28B) utility requires further definition.
- Add-on IFN to entecavir may shorten nucleos(t)ide analogue treatment in HBeAg-positive patients.
- A stopping rule based on HBsAg and HBV DNA decline at 12/24 weeks can identify non-responders in HBeAg-negative disease.
- Prolonging IFN to 96 weeks may improve response rates in HBeAg-negative patients.
- Combination of telbivudine and IFN is contraindicated due to peripheral neuropathy risk.
Conclusions:
- Findings suggest potential for optimized IFN strategies in chronic hepatitis B.
- Further validation in larger clinical trials is necessary before routine implementation.
- Careful patient selection and monitoring are essential for effective IFN therapy.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
32
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
01:25Hepatitis
42
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
01:29Viruses with RNA Genomes
1.3K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.3K
01:29Immune Response Against Viral Pathogens
2.5K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.5K